5930. Monitoring inequalities is a key part of the efforts to end AIDS, tuberculosis, and malaria.
作者: Ahmad Reza Hosseinpoor.;Nicole Bergen.;Katherine Kirkby.;Anne Schlotheuber.;Cecilia Vidal Fuertes.;Stephen Mac Feely.;Samira Asma.
来源: Lancet. 2022年399卷10331期1208-1210页 5931. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
作者: Qingyang Shi.;Yang Wang.;Qiukui Hao.;Per Olav Vandvik.;Gordon Guyatt.;Jing Li.;Zhe Chen.;Shishi Xu.;Yanjiao Shen.;Long Ge.;Feng Sun.;Ling Li.;Jiajie Yu.;Kailei Nong.;Xinyu Zou.;Siyi Zhu.;Cong Wang.;Shengzhao Zhang.;Zhi Qiao.;Zhongyu Jian.;Ya Li.;Xinyi Zhang.;Kerun Chen.;Furong Qu.;Yuan Wu.;Yazhou He.;Haoming Tian.;Sheyu Li.
来源: Lancet. 2022年399卷10321期259-269页
Pharmacotherapy provides an option for adults with overweight and obesity to reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for the benefits and harms of weight-lowering drugs.
5934. The Lancet Commission on the future of care and clinical research in autism.
作者: Catherine Lord.;Tony Charman.;Alexandra Havdahl.;Paul Carbone.;Evdokia Anagnostou.;Brian Boyd.;Themba Carr.;Petrus J de Vries.;Cheryl Dissanayake.;Gauri Divan.;Christine M Freitag.;Marina M Gotelli.;Connie Kasari.;Martin Knapp.;Peter Mundy.;Alex Plank.;Lawrence Scahill.;Chiara Servili.;Paul Shattuck.;Emily Simonoff.;Alison Tepper Singer.;Vicky Slonims.;Paul P Wang.;Maria Celica Ysrraelit.;Rachel Jellett.;Andrew Pickles.;James Cusack.;Patricia Howlin.;Peter Szatmari.;Alison Holbrook.;Christina Toolan.;James B McCauley.
来源: Lancet. 2022年399卷10321期271-334页 5935. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
作者: Arabella S V Stuart.;Robert H Shaw.;Xinxue Liu.;Melanie Greenland.;Parvinder K Aley.;Nick J Andrews.;J C Cameron.;Sue Charlton.;Elizabeth A Clutterbuck.;Andrea M Collins.;Tom Darton.;Tanya Dinesh.;Christopher J A Duncan.;Anna England.;Saul N Faust.;Daniela M Ferreira.;Adam Finn.;Anna L Goodman.;Christopher A Green.;Bassam Hallis.;Paul T Heath.;Helen Hill.;Bryn M Horsington.;Teresa Lambe.;Rajeka Lazarus.;Vincenzo Libri.;Patrick J Lillie.;Yama F Mujadidi.;Ruth Payne.;Emma L Plested.;Samuel Provstgaard-Morys.;Maheshi N Ramasamy.;Mary Ramsay.;Robert C Read.;Hannah Robinson.;Gavin R Screaton.;Nisha Singh.;David P J Turner.;Paul J Turner.;Iason Vichos.;Rachel White.;Jonathan S Nguyen-Van-Tam.;Matthew D Snape.; .
来源: Lancet. 2022年399卷10319期36-49页
Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer-BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).
|